The US and Mexico reached a preliminary agreement in principle to revise the North America Free Trade Agreement (NAFTA) with a contentious provision for the biosimilars industry: it would establish 10 years of data protection for biologics.
That term is longer than that provided in the US under the Biologics Price Competition and Innovation Act, which gives...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?